UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO^® and EPSOLAY^®, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

Read more at globenewswire.com